Kohlberg Kravis Roberts & Co. L.P. - INTERCEPT PHARMACEUTICALS IN ownership

INTERCEPT PHARMACEUTICALS IN's ticker is and the CUSIP is 45845PAB4. A total of 22 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.2%.

Quarter-by-quarter ownership
Kohlberg Kravis Roberts & Co. L.P. ownership history of INTERCEPT PHARMACEUTICALS IN
ValueSharesWeighting
Q2 2021$34,235,000
+40.5%
51,050,000
+34.2%
0.14%
+13.0%
Q1 2021$24,362,000
+709.9%
38,050,000
+661.0%
0.12%
+720.0%
Q4 2020$3,008,0005,000,0000.02%
Other shareholders
INTERCEPT PHARMACEUTICALS IN shareholders Q4 2020
NameSharesValueWeighting ↓
HIGHBRIDGE CAPITAL MANAGEMENT LLC 27,943,000$20,241,0001.72%
Worth Venture Partners, LLC 1,569,000$1,134,0000.56%
Context Capital Management, LLC 1,985,000$1,424,0000.55%
ADVENT CAPITAL MANAGEMENT /DE/ 16,703,000$12,060,0000.28%
CSS LLC/IL 6,825,000$4,985,0000.28%
SILVERBACK ASSET MANAGEMENT LLC 1,500,000$1,095,0000.27%
Polar Asset Management Partners Inc. 20,000,000$14,452,0000.24%
Senvest Management, LLC 5,000,000$3,621,0000.23%
FARALLON CAPITAL MANAGEMENT LLC 25,500,000$18,998,0000.15%
LINDEN ADVISORS LP 12,755,000$9,258,0000.15%
View complete list of INTERCEPT PHARMACEUTICALS IN shareholders